Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.

Authors :: Kim S
Tiedt R
Loo A
Horn T
Delach S
Kovats S
Haas K
Engstler BS
Cao A
Pinzon-Ortiz M
Mulford I
Acker MG
Chopra R
Brain C
Tomaso ED
Sellers WR
Caponigro G
Source :: Oncotarget [Oncotarget] 2020 Apr 07; Vol. 11 (14), pp. 1289. Date of Electronic Publication: 2020 Apr 07 (Print Publication: 2020).
Publication Year :: 2020
Abstract: [This corrects the article DOI: 10.18632/oncotarget.26215.].<br /> (Copyright: © 2019 Kim et al.)

Full Text Access

Tools